Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Scott Randall Plotkin, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Scott Plotkin and Vanessa Merker.
Connection Strength

8.070
  1. Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. Am J Med Genet A. 2022 Sep; 188(9):2672-2683.
    View in: PubMed
    Score: 0.979
  2. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv Res. 2018 Aug 29; 18(1):668.
    View in: PubMed
    Score: 0.754
  3. Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History Study. Otol Neurotol. 2016 06; 37(5):574-9.
    View in: PubMed
    Score: 0.645
  4. Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1. Fertil Steril. 2015 Mar; 103(3):761-8.e1.
    View in: PubMed
    Score: 0.585
  5. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A. 2014 Jun; 164A(6):1431-7.
    View in: PubMed
    Score: 0.554
  6. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012; 17(10):1317-22.
    View in: PubMed
    Score: 0.497
  7. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med. 2022 Sep; 24(9):1967-1977.
    View in: PubMed
    Score: 0.245
  8. Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Orphanet J Rare Dis. 2022 02 10; 17(1):44.
    View in: PubMed
    Score: 0.239
  9. Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS. Neurology. 2021 08 17; 97(7 Suppl 1):S4-S14.
    View in: PubMed
    Score: 0.230
  10. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021 08; 23(8):1506-1513.
    View in: PubMed
    Score: 0.228
  11. The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet J Rare Dis. 2021 02 01; 16(1):61.
    View in: PubMed
    Score: 0.223
  12. Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Educ Couns. 2021 04; 104(4):808-814.
    View in: PubMed
    Score: 0.218
  13. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. Otol Neurotol. 2018 06; 39(5):632-638.
    View in: PubMed
    Score: 0.185
  14. Pain correlates with germline mutation in schwannomatosis. Medicine (Baltimore). 2018 Feb; 97(5):e9717.
    View in: PubMed
    Score: 0.181
  15. Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. J Neurooncol. 2018 Jan; 136(2):335-342.
    View in: PubMed
    Score: 0.178
  16. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT. Neurology. 2016 Aug 23; 87(8):806-14.
    View in: PubMed
    Score: 0.163
  17. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J Clin Oncol. 2016 05 10; 34(14):1669-75.
    View in: PubMed
    Score: 0.159
  18. Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system. Am J Obstet Gynecol. 2015 Jul; 213(1):108-109.
    View in: PubMed
    Score: 0.147
  19. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol. 2015 Apr; 122(2):219-28.
    View in: PubMed
    Score: 0.147
  20. Examining perceived cancer risk among patients with neurofibromatosis type 1. J Neurooncol. 2015 Mar; 122(1):127-33.
    View in: PubMed
    Score: 0.146
  21. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion. Clin Nucl Med. 2014 May; 39(5):e301-7.
    View in: PubMed
    Score: 0.140
  22. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol. 2014 Jun; 73(6):1197-204.
    View in: PubMed
    Score: 0.139
  23. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol. 2014 Jan; 35(1):e50-6.
    View in: PubMed
    Score: 0.136
  24. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013 Sep; 114(3):257-62.
    View in: PubMed
    Score: 0.132
  25. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One. 2013; 8(3):e59941.
    View in: PubMed
    Score: 0.129
  26. Plasma S100ß is not a useful biomarker for tumor burden in neurofibromatosis. Clin Biochem. 2013 May; 46(7-8):698-700.
    View in: PubMed
    Score: 0.127
  27. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012 Aug; 33(6):1046-52.
    View in: PubMed
    Score: 0.124
  28. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One. 2012; 7(4):e35711.
    View in: PubMed
    Score: 0.121
  29. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S32-S41.
    View in: PubMed
    Score: 0.057
  30. First report of factors associated with satisfaction in patients with neurofibromatosis. Am J Med Genet A. 2017 03; 173(3):671-677.
    View in: PubMed
    Score: 0.042
  31. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. J Neurooncol. 2017 01; 131(2):413-419.
    View in: PubMed
    Score: 0.042
  32. Creation of an international registry to support discovery in schwannomatosis. Am J Med Genet A. 2017 Feb; 173(2):407-413.
    View in: PubMed
    Score: 0.041
  33. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand. 2016 Jun; 133(6):475-80.
    View in: PubMed
    Score: 0.038
  34. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol. 2014 Oct; 120(1):103-9.
    View in: PubMed
    Score: 0.035
  35. Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol. 2013 Feb; 55(2):146-53.
    View in: PubMed
    Score: 0.032
  36. Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis. Skeletal Radiol. 2012 Aug; 41(8):917-23.
    View in: PubMed
    Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.